The PIPE includes common stock and pre-funded warrants

Davis Polk is advising the placement agents in connection with a private placement of 16,973,103 shares of common stock of Solid Biosciences Inc. at a price of $5.53 per share and, in lieu of common stock, pre-funded warrants to purchase up to 2,712,478 shares of common stock at a price of $5.529 per pre-funded warrant.

Solid intends to use the proceeds from the offering to fund ongoing pipeline development programs, business development activities and for working capital and other general corporate purposes.

Headquartered in Charlestown, Massachusetts, Solid is a life sciences company focused on advancing a portfolio of gene therapy candidates and neuromuscular and cardiac programs, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, AVB-202-TT for the treatment of Friedreich’s ataxia and additional assets for the treatment of fatal cardiac diseases.

The Davis Polk corporate team includes partners Deanna L. Kirkpatrick and Yasin Keshvargar and counsel Michael Stromquist. All members of the Davis Polk team are based in the New York office.

Copy link to share post